Oncimmune discuss their highly profitable ImmunoINSIGHTS business

Oncimmune CEO, Dr Adam M Hill, discusses how the highly profitable ImmunoINSIGHTS business, the Company’s autoantibody profiling service, is used by their big pharma clients and their fixed pricing model. Adam goes on to discusses the lack of competition and how they are only addressing circa 3% of a huge markets but the the hiring of key staff and increasing the business development team in the UK and the USA will allow further growth.

You might like

© 2022 Stockmark.it The Latest StockMarket News and Interviews